ANNAPOLIS – Biodefense firm PharmAthene will sell $3.9 million of its common stock and warrants to an existing institutional investor in a registered public offering.
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1323698127.gif)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1270748889.png)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1286484661.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1312923369.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1313587373.gif)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1268857522.jpg)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1270748904.png)
![[Advertisement Image]](http://www.arundelbusinessnews.com/wp-content/uploads/groove-ads/1286484732.jpg)
- Chris O. posts (101)
- defense & homeland security (105)
- energy & green business (91)
- financial services (135)
- general business (477)
- gov't-quasi gov't (147)
- Guest Columnists (6)
- health care (102)
- non profit (53)
- professional Services (44)
- real estate-construction (172)
- technology-telecom (403)
- Uncategorized (2)
2013 Archives
Yearly Archives